Scholarlink

<p>Prenatal therapies represent an emerging frontier in healthcare, enabling medical intervention at the fetal stage to address severe congenital conditions before irreversible harm occurs. As these transformative interventions transition from bench to bedside, significant ethical, legal, and governance challenges arise, particularly concerning maternal-fetal risk-benefit dynamics, informed consent, and regulatory oversight. Recognizing the need for structured and adaptive ethical guidance, we propose a “Points to Consider” (P2C) Framework, developed through a multidisciplinary initiative involving experts in drug development, bioethics norms, human rights, and governance, based on a review of international scientific, regulatory, and ethical literature. The P2C integrates those considerations into nine thematic points addressing: maternal and fetal well-being; risk-benefit assessment, responsible research and clinical care, emerging technology, public engagement, funding sustainability, public health integration, lifecycle governance, and international collaboration. The P2C is designed to support the entire research-to-clinic continuum, fostering multidisciplinary global dialogue. By anchoring prenatal therapeutic innovations within international human rights norms, bioethics standards, and anticipatory governance practices, the P2C aims to ensure that future interventions are safe, ethically robust, and socially aligned. This initiative lays the groundwork for responsibly navigating the complex ethical landscape of prenatal medicine, with implications for policy, clinical practice, and global health equity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prenatal therapies: a Points to Consider framework for responsible innovation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月5日

查看全文
  • Eric M. Meslin,
  • Caroline Kant,
  • Sebastien Mazzuri,
  • Bartha Maria Knoppers

摘要

Prenatal therapies represent an emerging frontier in healthcare, enabling medical intervention at the fetal stage to address severe congenital conditions before irreversible harm occurs. As these transformative interventions transition from bench to bedside, significant ethical, legal, and governance challenges arise, particularly concerning maternal-fetal risk-benefit dynamics, informed consent, and regulatory oversight. Recognizing the need for structured and adaptive ethical guidance, we propose a “Points to Consider” (P2C) Framework, developed through a multidisciplinary initiative involving experts in drug development, bioethics norms, human rights, and governance, based on a review of international scientific, regulatory, and ethical literature. The P2C integrates those considerations into nine thematic points addressing: maternal and fetal well-being; risk-benefit assessment, responsible research and clinical care, emerging technology, public engagement, funding sustainability, public health integration, lifecycle governance, and international collaboration. The P2C is designed to support the entire research-to-clinic continuum, fostering multidisciplinary global dialogue. By anchoring prenatal therapeutic innovations within international human rights norms, bioethics standards, and anticipatory governance practices, the P2C aims to ensure that future interventions are safe, ethically robust, and socially aligned. This initiative lays the groundwork for responsibly navigating the complex ethical landscape of prenatal medicine, with implications for policy, clinical practice, and global health equity.